Clinical trials located in

Cologne

Cologne city is located in Germany. Currently, 13 clinical trials are being conducted in this city.

Cologne, located in western Germany along the Rhine River, is one of the country’s oldest cities, founded by the Romans in 50 AD. It is renowned for its impressive Gothic architecture, notably the Cologne Cathedral (Kölner Dom), which houses the Shrine of the Three Kings. The city is also famous for its vibrant arts scene, numerous museums, and the annual Cologne Carnival, one of Europe’s largest street festivals. Cologne is a significant cultural and historical center, with a rich tradition in the production of Eau de Cologne, a fragrance that has gained worldwide recognition.

  • CT-EU-00112349

    Testing New Therapies for Glioblastoma Brain Cancer

    Howdy there, partner! This here trial is called the GBM AGILE study, and it’s aiming to find better treatments for a type of brain cancer called glioblastoma. Now, glioblastoma is a real tough customer, but this study is taking a new approach by testing multiple therapies all at once, both for newly diagnosed cases and for those where the cancer has come back.

    The main goal is to find treatments that work better and can be matched to different types of glioblastoma. The study uses a fancy method called Bayesian response adaptive randomization to assign folks to different treatment arms based on how well those treatments are performing. The most important measure they’re looking at is overall survival – how long patients live after starting treatment.

    Some of the therapies being tested include drugs like temozolomide, lomustine, regorafenib, paxalisib, VAL-083, VT1021, and troriluzole. These come in different forms like capsules, tablets, or infusions, and the dosages and schedules vary depending on the drug. The study is set up so that new promising therapies can be added in, and ones that aren’t working so well can be removed as the trial goes on.

    FranceGermany
  • Study of the effectiveness of a new drug in the treatment of heart failure and pulmonary hypertension

    This clinical trial explores the potential benefits of AZD3427 for individuals with heart failure (HF) and pulmonary hypertension (PH) Group 2, a condition characterized by increased blood pressure in the lungs due to heart disease. Around 220 participants will be randomly assigned to receive either AZD3427 or a placebo through subcutaneous injections every two weeks for 24 weeks. The trial aims to assess the impact of AZD3427 on reducing pulmonary vascular resistance (PVR) and improving various heart and lung health indicators. Participants will undergo multiple study visits, with the total duration of the study being approximately 32 to 37 weeks.

    AustriaCzechiaDenmarkGermanyItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Esophageal cancer treatment study: Durvalumab & radiochemotherapy

    The RICE study is a Phase II trial for patients with esophageal adenocarcinoma. It tests adding durvalumab to standard neoadjuvant radiochemotherapy, followed by surgery. The trial evaluates safety, efficacy (aiming to increase the pathological complete response rate), and biomarker response to immune checkpoint inhibition. Participants will be randomized into groups receiving durvalumab with or without tremelimumab, alongside their radiochemotherapy.

    Germany
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Comparison of new treatment and standard care for lymphoma patients

    A new approach to treating Lymphoma, a type of cancer originating in cells constituting the body’s immune system, is being tested in this trial. Comparison is being made between a new treatment, referred to as MB-CART2019.1, and the presently conventional treatment. The MB-CART2019.1 therapy is designed to target the aberrant B cells responsible for this form of cancer. In the process of creating MB-CART2019.1, cells are extracted from the patient’s own body, modified in the laboratory to combat cancer, and subsequently reintroduced into the patient. Participants in this trial will receive either MB-CART2019.1 or the standard treatment. The standard treatment involves the use of a drug combination (rituximab, gemcitabine, oxaliplatin (R-GemOx) or bendamustine, rituximab (BR) + polatuzumab vedotin). The objective is to assess whether MB-CART2019.1 demonstrates superior efficacy compared to these conventional drugs. Patient progress will be closely monitored for approximately one year to evaluate their well-being.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandSpainSweden
  • Investigating opelconazole treatment for refractory invasive pulmonary aspergillosis

    In this study, we are testing a medication called PC945 (also known as opelconazole) to see if it is safe and effective in treating a lung infection called ‘Refractory Invasive Pulmonary Aspergillosis’ or IPA. The medication is used with other antifungal medicines to provide a combined treatment. The researchers will be checking how well this treatment works and if there are any side effects. Some people in the study will get the medicine and others will get a placebo (no active ingredients) along with the antifungal medicine. This process is done in a random and blind way – meaning neither the patient nor the doctors know who is getting the real or placebo medicine.

    AustriaBelgiumFranceGermanyGreeceItalySpainUnited Kingdom
  • Testing new drug on long-term COVID-19 symptoms

    This study is exploring the effectiveness and safety of a treatment called BC 007 in individuals suffering from Long COVID. Long COVID is the prolonged health impact seen in some people after a COVID-19 infection, often marked by fatigue, breathing difficulties, and other persistent symptoms. BC 007 works by targeting and neutralizing certain autoantibodies (proteins made by the immune system) which are contributed to these lingering symptoms. The treatment involves two intravenous infusions of BC 007 or a placebo, followed by regular monitoring for about a year. The goal is to understand if BC 007 can alleviate the long-term effects of COVID-19 in patients who had not been severely ill (not needing intubation or ECMO) during their initial infection.

    AustriaFinlandGermanySpain
  • Tolvaptan safety study for young patients with kidney disease

    This clinical trial evaluates the safety of tolvaptan in infants and children with autosomal recessive polycystic kidney disease (ARPKD). The study will monitor young patients’ kidney function and any side effects they experience while taking tolvaptan for 18 months. The orally administered medicine comes in two forms: a suspension for people who cannot swallow tablets, and tablets for older children. The aim is to see if tolvaptan, which has already been shown to be helpful in adults with similar kidney disease, could also benefit children with ARPKD by slowing the progression of kidney disease.

    BelgiumGermanyItalyPolandUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Study of a new drug in children with shortness of breath and wheezing

    This study focuses on Broncho-Vaxom (OM-85), a medication intended to assist children who frequently experience chest infections and encounter difficulties such as wheezing or shortness of breath. The trial is set up to compare three groups of kids from 6 months to 5 years old. The first group will get Broncho-Vaxom (OM-85) for a whole year, the second group will get OM-85 for three months and then a placebo for nine months, and the third will only get the placebo for a year. Observations will be conducted on the children for a year and a half to assess whether there is a reduction in chest infections while they are taking the medication.

    GermanyHungaryItalyPolandUnited Kingdom
  • Improvement of multiple myeloma treatment with the use of daratumumab in patients ineligible for transplant.

    This study aims to evaluate the safety and effectiveness of daratumumab combined with a standard induction treatment (bortezomib, cyclophosphamide, and dexamethasone) in transplant-ineligible multiple myeloma patients. The trial will also assess the effectiveness of daratumumab as part of maintenance therapy combined with bortezomib and dexamethasone. Finally, the study will examine the efficacy of a daratumumab-containing regimen for patients who have relapsed after their initial daratumumab treatment.

    Germany

See more clinical trials in other cities in Germany:

.